Skip to main content

Table 1 Baseline and TB-IRIS characteristics of the 212 patients included in Cox proportional hazards model

From: Prolonged tuberculosis-associated immune reconstitution inflammatory syndrome: characteristics and risk factors

Variable Median (interquartile range) or number (%)
Gender (n = 212)
 Female 138 (65.1 %)
 Male 74 (34.9 %)
Age (years) (n = 212) 31 (27, 36)
WHO stage (n = 212)
 3 71 (33.5 %)
 4 141 (66.5 %)
CD4 count prior to ART (cells/μl) (n = 199) 52 (28, 92.5)
CD4 count at TB-IRIS (cells/μl) (n = 95) 116 (71, 209.5)
Previous TB (n = 211) 55 (25.9 %)
Drug-resistant TB (n = 212)a 21 (10 %)
Initial TB diagnosis with extra-pulmonary involvement (n = 212) 134 (63.2 %)
Initial TB diagnosis with lymph node involvement (n = 212) 50 (23.6 %)
Duration from TB treatment to ART (days) (n = 211) 56 (31, 83)
Duration from ART to TB-IRIS onset (days) (n = 211) 14 (7, 21)
Hospitalised at time of TB-IRIS diagnosis (n = 206) 107 (50.5 %)
TB-IRIS lymph node involvement (n = 212) 80 (37.7 %)
TB-IRIS pulmonary involvement (n = 212) 83 (39.2 %)
TB-IRIS meningitis (n = 209) 10 (4.7 %)
TB-IRIS abdominal involvement (n = 212) 154 (72.6 %)
TB-IRIS multisystem involvement (n = 212) 166 (78.3 %)
Pulse rate (n = 134) 120 (107.3, 132)
C-reactive protein (mg/l) (n = 195) 103 (63, 158.5)
Haemoglobin (g/dl) (n = 136) 9.1 (8, 10.4)
White cell count
(× 109/l) (n = 132)
5.7 (4.1, 8.1)
ALT (IU/l) (n = 180) 34 (22, 51)
Alkaline phosphatase (IU/l) (n = 164) 159 (107, 274.8)
Corticosteroid treatment for TB-IRIS 125 (59.0 %)
  1. Pulse rate and laboratory values refer to the value obtained when the patient was first assessed with TB-IRIS symptoms, unless otherwise stated. Numbers in brackets after the variable name refer to the number of patients for whom that variable was available
  2. Abbreviations: ALT alanine transferase, ART antiretroviral therapy, IRIS immune reconstitution inflammatory syndrome, TB tuberculosis, WHO World Health Organisation
  3. aAmong 21 patients with drug resistant TB: four had rifampicin mono-resistance, three had isoniazid mono-resistance and 14 had resistance to rifampicin and isoniazid